Invesco NASDAQ Biotechnology ETFIBBQ
IBBQ
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
47% more funds holding
Funds holding: 15 [Q2] → 22 (+7) [Q3]
16% more capital invested
Capital invested by funds: $9.93M [Q2] → $11.6M (+$1.63M) [Q3]
4.52% less ownership
Funds ownership: 35.67% [Q2] → 31.15% (-4.52%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for IBBQ.
Financial journalist opinion
Positive
Seeking Alpha
3 months ago
IBBQ: This Low-Cost Biotech ETF Comes With Unique Risks
IBBQ is a relatively new U.S. biotech ETF that competes with established peers like IBB and XBI. IBBQ has outperformed both since its June 2021 launch date. However, there are specific risks investors should consider first. In addition to the volatile nature of the biotech industry, I'll review IBBQ's liquidity, concentration, and quality features in detail. IBBQ also has a high liquidation risk. With only $38 million in assets under management and a 0.19% expense ratio, IBBQ likely isn't a profitable product for Invesco.
Positive
ETF Trends
9 months ago
Biotech Rally in Its Early Innings
Following a multiyear run of disappointment, biotech stocks and related ETFs are showing signs of life. For the past 90 days ending February 29, the widely observed Nasdaq Biotechnology Index was higher by almost 17%.
Positive
Zacks Investment Research
9 months ago
6 Factors to Bet on Wall Street: ETFs to Buy
The Nasdaq Composite and the S&P 500 hit new all-time high Friday. However, there are chances of further rally.
Positive
Zacks Investment Research
11 months ago
Biotech ETFs Stage Solid Comeback at the Start of 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Positive
Zacks Investment Research
11 months ago
5 Top-Ranked ETF Winners of December With More Room for Gains
Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings.
Charts implemented using Lightweight Charts™